What doesn’t kill you: primed and adaptive mechanisms of treatment resistance in ovarian cancer

This project aims to develop a novel methodology to identify and target pre-existing resistant cell states in ovarian cancer, enhancing therapy effectiveness through sequential drug combinations.

Subsidie
€ 1.999.754
2024

Projectdetails

Introduction

Cancer therapy resistance is a complex, dynamic process. Pre-existing heterogeneity in cell states provides substance for evolutionary selection, and their plasticity enables adaptation during the therapy. Recently, we discovered a stress-related, immunocompromised cell state underpinning both intrinsic and adaptive resistance in high-grade serous ovarian cancer (HGSC) metastatic tumours, suggesting that pre-existing stress improves the resilience of cancer cells during neoadjuvant chemotherapy.

Proposed Approach

To unveil how past stress responses prime cancer cells’ adaptation during therapies, I suggest a novel approach that combines dynamic stress recording with the identification of pre-existing resistant states via my novel methodology, ReSisTrace.

Application in Patient-Derived Organoids

We will apply this ground-breaking approach in patient-derived organoids to reveal how past stress signalling of a single cell is reflected in its adaptive stress responses and survival upon chemotherapy or cytotoxic immune attack.

Characterisation of Resistant Phenotypes

We will further characterise subclonal and spatial enrichment of the identified resistant phenotypes in longitudinal clinical specimens to incorporate the effect of the tumour microenvironment in discovered mechanisms.

Overcoming Resistance

Importantly, simultaneous characterisation of primed and adaptive resistance enables us to overcome both of them by a sequential combination of drugs:

  1. The first drug will drive cells to identified sensitive states prior to treatment.
  2. The second drug will block identified adaptive responses during the treatment.

Validation of Drug Combinations

After finding the most effective pre-sensitisers and anti-adaptive drugs in the organoids, we will validate the most promising combinations in patient-derived xenograft models to pave the way for clinical translation.

Conclusion

By targeting both pre-existing cell states and their plasticity, my novel approach will lead to a paradigm shift by providing novel, sequential therapeutic strategies to mutually overcome intrinsic and adaptive resistance in the treatment of cancer.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.999.754
Totale projectbegroting€ 1.999.754

Tijdlijn

Startdatum1-4-2024
Einddatum31-3-2029
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • HELSINGIN YLIOPISTOpenvoerder

Land(en)

Finland

Vergelijkbare projecten binnen European Research Council

ERC Consolid...

Cancer cell plasticity on targeted therapy

This project aims to develop innovative cancer therapies by analyzing tumor heterogeneity and targeting drug-tolerant persister cells to prevent resistance and improve patient outcomes.

€ 2.000.000
ERC Advanced...

Paradoxical activation of oncogenic signaling as a cancer treatment strategy.

This project aims to selectively kill cancer cells by hyperactivating oncogenic signaling while disrupting stress responses, using multi-omics to identify vulnerabilities and effective combination therapies.

€ 2.500.000
ERC Starting...

Precision oncology of spatial immune escape mechanisms in ovarian cancer

This project aims to exploit tumor genetic drivers of immune escape in high-grade serous ovarian cancer to develop effective immunotherapies through advanced profiling and functional testing of patient-derived organoids.

€ 2.368.459
ERC Consolid...

Dynamics of Adaptation and Resistance in Cancer: MApping and conTrolling Transcriptional and Epigenetic Recurrence

This project aims to uncover the mechanisms of drug resistance in colorectal cancer through innovative models and computational methods, ultimately improving treatment strategies and patient outcomes.

€ 1.995.582
ERC Starting...

Understanding and targeting cancer persister cells

This project aims to develop tools for studying cancer persister cells using single-cell lineage tracing to enhance understanding and treatment of therapy-resistant tumors.

€ 1.728.750

Vergelijkbare projecten uit andere regelingen

EIC Transition

Macrophage-based immunotherapy of platinum-resistant ovarian cancer

The MACOV project aims to develop a groundbreaking macrophage-based therapy for platinum-resistant ovarian cancer, preparing it for Phase I clinical trials through comprehensive pre-clinical efficacy and safety studies.

€ 2.499.998
EIC Pathfinder

Functional chemical reprogramming of cancer cells to induce antitumor immunity

The RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments.

€ 2.966.695